Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCRTR1 | O43613 | 16/20 | 0.42 |
| ▸ | HCRTR2 | O43614 | 16/20 | 0.42 |
| ▸ | HCAR1 | Q9BXC0 | 2/20 | 0.41 |
| ▸ | RXRA | P19793 | 1/20 | 0.37 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.37 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14850900 | 0.79 | ADRB1 (0.44) | HCRTR1HCRTR2HCAR1 | |
| SCHEMBL17145963 | 0.79 | MGLL (0.43) | HCRTR1HCRTR2 | |
| SCHEMBL16787393 | 0.76 | HCAR1 (0.38) | HCRTR1HCRTR2HCAR1RXRAGRIN1 | |
| SCHEMBL18195988 | 0.76 | HCRTR1 (0.38) | HCRTR1HCRTR2 | |
| SCHEMBL14883121 | 0.76 | HCRTR1 (0.38) | HCRTR1HCRTR2 | |
| SCHEMBL18367716 | 0.73 | CA2 (0.38) | HCRTR1HCRTR2 | |
| SCHEMBL19732402 | 0.73 | GABRA1 (0.38) | HCRTR1HCRTR2 | |
| SCHEMBL16025401 | 0.73 | HCRTR1 (0.49) | HCRTR1HCRTR2 | |
| SCHEMBL10262360 | 0.72 | HCRTR1 (0.34) | HCRTR1HCRTR2 | |
| SCHEMBL14886142 | 0.72 | ACHE (0.43) | HCRTR1HCRTR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4310089-A1 | NITROGEN-CONTAINING HETEROCYCLIC POLYCYCLIC COMPOUND, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | Shanghai Hansoh Biomedical Co., Ltd. (CN) | 2024-01-24 | — | — | EP | disclosed |
| US-11040966-B2 | Benzimidazole-proline derivatives | IDORSIA PHARMACEUTICALS LTD (CH) | 2021-06-22 | — | — | US | disclosed |
| US-20190263797-A1 | BENZIMIDAZOLE-PROLINE DERIVATIVES | IDORSIA PHARMACEUTICALS LTD (CH) | 2019-08-29 | — | — | US | disclosed |
| US-10329287-B2 | Benzimidazole-proline derivatives | IDORSIA PHARMACEUTICALS LTD (CH) | 2019-06-25 | — | — | US | disclosed |
| EP-3115362-B1 | PIPERIDINE DERIVATIVES AS OREXIN RECEPTOR ANTAGONIST | SHANGHAI HAIYAN PHARMACEUTICAL TECH CO LTD (CN) | 2019-06-12 | — | — | EP | disclosed |
| US-20170305897-A1 | BENZIMIDAZOLE-PROLINE DERIVATIVES | IDORSIA PHARMACEUTICALS LTD (CH) | 2017-10-26 | — | — | US | disclosed |
| US-20170305897-A1 | BENZIMIDAZOLE-PROLINE DERIVATIVES | IDORSIA PHARMACEUTICALS LTD (CH) | 2017-10-26 | — | — | US | disclosed |
| EP-2768823-B1 | 2-PYRIDYLOXY-4-NITRILE OREXIN RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME (US) | 2017-09-06 | — | — | EP | disclosed |
| US-20170233385-A1 | PIPERIDINE DERIVATIVES AS OREXIN RECEPTOR ANTAGONIST | SHANGHAI HAIYAN PHARMACEUTICAL TECHNOLOGY CO., LTD. (CN) | 2017-08-17 | — | — | US | disclosed |
| US-9732075-B2 | Benzimidazole-proline derivatives | IDORSIA PHARMACEUTICALS LTD (CH) | 2017-08-15 | — | — | US | disclosed |
| US-20150158855-A1 | 2-(1,2,3-TRIAZOL-2-YL)BENZAMIDE AND 3-(1,2,3-TRIAZOL-2-YL)PICOLINAMIDE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD. (CH) | 2015-06-11 | — | — | US | disclosed |
| US-20150158855-A1 | 2-(1,2,3-TRIAZOL-2-YL)BENZAMIDE AND 3-(1,2,3-TRIAZOL-2-YL)PICOLINAMIDE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD. (CH) | 2015-06-11 | — | — | US | disclosed |
| EP-2454252-B1 | Spiro amino compounds suitable for the treatment of (inter alia) sleep disorders and drug addiction | Rottapharm Biotech Srl (IT) | 2015-03-04 | — | — | EP | disclosed |
| US-8859608-B2 | Spiro amino compounds suitable for the treatment of inter alia sleep disorders and drug addiction | ROTTAPHARM BIOTECH S.R.L. (IT) | 2014-10-14 | — | — | US | disclosed |
| WO-2013059222-A1 | 2-PYRIDYLOXY-4-NITRILE OREXIN RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2013-04-25 | — | — | WO | disclosed |
| WO-2013050938-A1 | 3,7-DIAZABICYCLO[3.3.1]NONANE AND 9-OXA-3,7-DIAZABICYCLO[3.3.1]NONANE DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2013-04-11 | — | — | WO | disclosed |
| WO-2012085852-A1 | 3,8-DIAZA-BICYCLO[4.2.0]OCT-8-YL AMIDES | ACTELION PHARMACEUTICALS LTD (CH) | 2012-06-28 | — | — | WO | disclosed |
| WO-2012085857-A1 | 3,8-DIAZA-BICYCLO[4.2.0]OCT-3-YL AMIDES | ACTELION PHARMACEUTICALS LTD (CH) | 2012-06-28 | — | — | WO | disclosed |
| US-20120115882-A1 | SPIRO AMINO COMPOUNDS SUITABLE FOR THE TREATMENT OF INTER ALIA SLEEP DISORDERS AND DRUG ADDICTION | ROTTAPHARM BIOTECH S.R.L. (IT) | 2012-05-10 | — | — | US | disclosed |
| WO-2011006960-A1 | SPIRO AMINO COMPOUNDS SUITABLE FOR THE TREATMENT OF INTER ALIA SLEEP DISORDERS AND DRUG ADDICTION | ROTTAPHARM S.P.A. (IT) | 2011-01-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150158855-A1 | 2-(1,2,3-TRIAZOL-2-YL)BENZAMIDE AND 3-(1,2,3-TRIAZOL-2-YL)PICOLINAMIDE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS | HCRTR2, HCRTR1, NPY1R | HCRTR1 2/4885HCRTR2 1/4885HCAR1 132/4885 |
| US-10329287-B2 | Benzimidazole-proline derivatives | HCRTR1, HCRTR2, NPY1R | HCRTR1 1/4885HCRTR2 2/4885HCAR1 102/4885 |
| US-11040966-B2 | Benzimidazole-proline derivatives | HCRTR1, HCRTR2, NPY1R | HCRTR1 1/4885HCRTR2 2/4885HCAR1 102/4885 |
| US-20120115882-A1 | SPIRO AMINO COMPOUNDS SUITABLE FOR THE TREATMENT OF INTER ALIA SLEEP DISORDERS AND DRUG ADDICTION | SLC1A1, SLC6A3, SLC1A2 | HCRTR1 15/4885HCRTR2 55/4885HCAR1 1042/4885 |
| US-20170233385-A1 | PIPERIDINE DERIVATIVES AS OREXIN RECEPTOR ANTAGONIST | HCRTR1, HCRTR2, OPRD1 | HCRTR1 1/4885HCRTR2 2/4885HCAR1 98/4885 |
| US-20190263797-A1 | BENZIMIDAZOLE-PROLINE DERIVATIVES | HCRTR1, HCRTR2, NPY1R | HCRTR1 1/4885HCRTR2 2/4885HCAR1 102/4885 |
| US-20170305897-A1 | BENZIMIDAZOLE-PROLINE DERIVATIVES | HCRTR1, HCRTR2, NPY1R | HCRTR1 1/4885HCRTR2 2/4885HCAR1 102/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.